Document:

AutoCoded Document

Exhibit
10.2

Paul
A.H. PANKOW

June 2, 2005 

Ramesh C,
Trivedi
CEO
Integrated Surgical Systems, Inc.

1850 Research Park Drive

Davis, CA 95816

Dr. Dr. Trivedi, 

I
enjoyed serving as a Director of ISS, but for personal reasons, I am resigning
from this position effective June 2, 2005. 

Sincerely, 

/s/   Paul
A.H. Pankow
       Paul A.H. PankowExhibit 4.1

    
      

    

    EXHIBIT
      4.1

    

    STOCK
      PURCHASE AGREEMENT

    

    STOCK
      PURCHASE AGREEMENT
      (this
“Agreement”),
      entered into as of and effective the 31st
      day of
      May 2005, by and among Sequiam
      Corporation,
      a
      California corporation (the “Buyer”)
      and
the
      individuals whose names appear on Exhibit
      A
      hereto (the
      “Shareholders”
      or
“Sellers”),
      and
Constellation
      Biometrics Corporation,
      a
      Florida corporation (the “Company”
      or
“Constellation”);

    

    W
      I T N E S S E T H:

    

    WHEREAS,
      the
      Company is engaged in the business of the development, marketing and sale of
      biometric technology products (the “Business”);
      and

    

    WHEREAS,
      the
      Company owns 100% of the outstanding capital stock of Biometrics.co.za, a
      company organized under the laws of South Africa (the “Subsidiary”);
      and

    

    WHEREAS,
      the
      Shareholders are the record owners of one hundred percent (100%) of the issued
      and outstanding capital stock of the Company (the “Stock”)
      as set
      forth opposite their respective names on Exhibit
      A
      attached
      hereto and made a part hereof; and 

    

    WHEREAS,
      the
      Shareholders had originally acquired their interests in the Company and the
      Subsidiary with a view toward combining the Company with the Buyer once the
      Buyer was able to arrange for the purchase of the Company and the Subsidiary;
      and

    

    WHEREAS,
      it is
      the intent of the parties that the Buyer stand in the place of the Shareholders
      in the acquisition, and that the Shareholders be reimbursed for their
      investment, without deriving any substantial profit on the transaction; and
      

    

    WHEREAS,
      the
      Buyer desires to purchase from the Shareholders, and the Shareholders desire
      to
      sell to the Buyer, upon the terms and subject to the conditions set forth in
      this Agreement, all (and not less than all) of the Stock, and through such
      Stock
      ownership of the Business as a going concern.

    

    NOW,
      THEREFORE,
      in
      consideration of the premises and the mutual covenants herein contained, the
      parties hereby agree as of the date hereof, as follows:

    

    1.    RECITALS.
      The
      foregoing recitals are true and accurate and by this reference incorporated
      herein.

    

    2.    ACQUISITION
      OF THE STOCK; CONSIDERATION.

    

    2.1    Purchase
      and Sale of Stock. Subject to the terms and conditions of this Agreement, at
      the Closing (defined below) the Buyer shall purchase and acquire from the
      Shareholders, and the Shareholders shall sell and transfer to the Buyer, all
      (and not less than all) of the Stock, in exchange for the consideration provided
      in Section 2.2. In furtherance thereof, the Shareholders shall deliver the
      certificates representing all of their Stock (duly endorsed for transfer or
      accompanied by stock powers executed in blank for transfer) to Buyer at
      Closing.

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    2.2    Consideration.
      In exchange for the shares of Stock owned by each Shareholder, the Buyer will
      issue and deliver to each Shareholder the number of shares of common stock
      of
      Buyer as set forth opposite each Shareholder’s name on Exhibit B attached
      hereto and made a part hereof, representing a total of 1,635,514 shares of
      common stock of Buyer (the “Sequiam
      Shares”).
      The
      exchange of stock for Sequiam Shares is intended to qualify as a tax-free
      exchange under Section 368(a)(1)(B) of the Internal Revenue Code of 1986, as
      amended, and regulations promulgated thereunder (collectively, the
“Code”).

    

    3.    CLOSING.

    

    3.1    Closing.
      Subject to the conditions stated in Section 8 and Section 9, the closing of
      the
      transactions contemplated hereby (the “Closing”)
      shall
      be held at 10:00 a.m., eastern time, on May 31, 2005, or if the conditions
      set
      forth in Section 8 or Section 9 have not been satisfied or waived on such date,
      on the fifth (5th)
      business day after all such conditions shall have been satisfied or waived
      (the
“Outside
      Closing Date”),
      at
      the offices of Greenberg Traurig, P.A., 450 South Orange Avenue, Suite 650,
      Orlando, Florida 32801, or at such other location, or such earlier or later
      date
      or time as the parties may mutually agree. The date upon which the Closing
      occurs is hereinafter referred to as the “Closing
      Date.”

    

    3.2    Deliveries
      by the Shareholder. At or prior to the Closing, the Shareholders shall
      deliver to the Buyer:

    

    (a)    stock
      certificates representing the Stock, duly endorsed by the Shareholders or
      accompanied by executed stock powers;

    

    (b)    a
      certificate executed by each Shareholder to the effect that the conditions
      set
      forth in Section 9 have been satisfied;

    

    (c)    any
      other
      documents or instruments deemed reasonably necessary by Buyer or Shareholder
      to
      consummate the transactions contemplated hereby.

    

    3.3    Deliveries
      by Buyer.

    

    (a)    the
      Sequiam Shares issued in the name of each Shareholder as set forth on
Exhibit
      B
      hereto,
      or alternatively the delivery of a letter to the Buyer’s transfer agent
      instructing the transfer agent to issue the Sequiam Shares to the Shareholders
      in accordance with Exhibit
      B;

    

    (b)    a
      certificate executed by the Buyer to the effect that the conditions set forth
      in
      Section 8 have been satisfied;

    

    (c)    a
      copy of
      resolutions adopted by Buyer’s Board of Directors authorizing the transactions
      contemplated herein and the issuance of the Sequiam Shares;

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    

    (d)    any
      other
      documents or instruments deemed reasonably necessary by Buyer or Shareholder
      to
      consummate the transactions contemplated hereby.

    

    3.4    Ancillary
      Documents. The following documents may be sometimes referred to herein
      collectively as the “Ancillary
      Documents”:
      any or
      all other agreements, instruments or documents required or expressly provided
      under this Agreement to be executed and delivered in connection with the
      transactions contemplated by this Agreement.

    

    3.5    Allocation
      of Closing Costs. All expenses incurred by the Buyer or the Shareholders in
      connection with the transactions contemplated hereby, including legal, financial
      advisory, accounting, and other expert fees, shall be the responsibility of
      and
      for the account of the party who ordered the particular service or incurred
      the
      particular expense.

    

    4.    REPRESENTATIONS
      AND WARRANTIES OF SHAREHOLDERS.

    

    In
      connection with the sale of the Stock to the Buyer, the Shareholders, each
      separately, only as such representation relates to each such Shareholder,
      represent and warrant to the Buyer as follows;

    

    4.1    Title
      to the Stock. The Shareholder is the valid and lawful record and beneficial
      owner of all of the Stock set forth opposite the Shareholder’s name on
Exhibit A hereto, all of which has been duly authorized and validly
      issued and is fully paid and non-assessable, and is free and clear of all
      pledges, liens, claims, charges, options, calls, encumbrances, restrictions
      and
      assessments whatsoever (except any restrictions which may be created by
      operation of state or federal securities laws). On the Closing Date, the Buyer
      shall receive from the Shareholder good, valid and marketable title to all
      of
      such Stock free and clear of all pledges, liens, claims, charges, options,
      calls, encumbrances, restrictions and assessments whatsoever (except any
      restrictions which may be created by operation of state or federal securities
      laws).

    

    4.2    Rights
      to Acquire Capital Stock.
      To the
      best of Shareholder’s knowledge, there are no outstanding subscriptions,
      options, rights, warrants, convertible securities or other agreements or calls,
      demands or commitments obligating the Company or the Subsidiary to issue,
      transfer or purchase any shares of its capital stock, or obligating the
      Shareholder to transfer any shares of Stock. 

    

    4.3    Valid
      and Binding Agreement; No Breach. 

    

    (a)    The
      Shareholder has full legal right, power and authority to execute and deliver
      this Agreement and to consummate the transactions contemplated hereby. This
      Agreement constitutes the legal, valid and binding obligations of the
      Shareholder, enforceable against the Shareholder in accordance with their
      respective terms, except as such enforcement may be limited by general equitable
      principles or by applicable bankruptcy, insolvency, reorganization or other
      laws
      and judicial decisions from time to time in effect which affect creditors’
      rights generally.

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

    

    

    4.4    Affiliated
      Transactions.
      Other
      than as disclosed in this Agreement (including any exhibits annexed hereto),
      neither the Company nor the Subsidiary is a debtor or creditor of the
      Shareholder, nor are the Company or the Subsidiary subject to any agreement
      between either of them and the Shareholder. 

    

    4.5    Brokers.
      No broker or finder is involved in this transaction or is entitled to receive
      a
      fee, commission or other compensation from the Shareholder or the Company with
      respect to the transactions contemplated in this Agreement.

    

    4.6    No
      Other Consideration. The only consideration being paid by the Shareholder
      for the Sequiam Shares is the Shareholder’s Stock and no other consideration in
      any form whatsoever, including but not limited to any real or personal property,
      securities or cash, has been or will be received by the Shareholder in exchange
      for the Shareholder’s Stock. 

    

    4.7    Investment
      Intent; Accredited Investor Status. Each Shareholder is an “accredited
      investor” within the meaning of Regulation D promulgated under the Securities
      Act of 1933, as amended (the “Securities
      Act”).
      The
      Shareholder is acquiring the Sequiam Shares for his own account for the purpose
      of investment and not with a view to, or for sale in connection with, the
      distribution thereof, and it has no present intention of distributing or selling
      such Sequiam Shares. The Shareholder understands that the Sequiam Shares have
      not been registered under the Securities Act, or the securities laws of any
      state or other jurisdiction, and hereby agrees not to make any sale, transfer
      or
      other disposition of such Sequiam Shares unless either (i) such Sequiam Shares
      have been registered under the Securities Act and all applicable state and
      other
      securities laws and any such registration remains in effect or (ii) Buyer shall
      have received an opinion of counsel in form and substance reasonably
      satisfactory to Buyer that registration is not required under the Securities
      Act
      or under applicable state securities laws.

    

    4.8    Opportunity
      to Investigate. The Shareholder (i) has received copies of the Buyer’s Form
      10-KSB for the fiscal year ended December 31, 2004 and subsequent filings of
      the
      Buyer made pursuant to the Securities and Exchange Act of 1934, as amended
      (the
“Exchange
      Act”)
      (ii)
      has had the opportunity to ask questions concerning Buyer and all such questions
      posed have been answered to his satisfaction; (ii) has been given the
      opportunity to obtain any additional information it deems necessary to verify
      the accuracy of any information obtained concerning Buyer; and (iii) has such
      knowledge and experience in financial and business matters that it is able
      to
      evaluate the merits and risks of the Buyer acquiring the Company and to make
      an
      informed investment decision relating thereto. The opportunity to so investigate
      Buyer and information obtained therefrom shall not affect the Shareholder’s
      representations and warranties set forth in this Agreement.

    

    5.    REPRESENTATIONS
      AND WARRANTIES OF THE BUYER.

    

    In
      connection with the Buyer’s purchase of the Stock from the Shareholder, the
      Buyer represents and warrants to the Shareholders as follows:

    

    5.1    Existence. The
      Buyer
      is now, and on the Closing Date will be, a corporation, organized and existing
      and in good standing under the laws of the State of California and has the
      requisite power and authority to own or lease its properties and to carry on
      its
      business as now being conducted.

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

    

    

    5.2    Power
      and Authority. The Buyer has the power, legal capacity and authority to
      enter into, and perform its obligations under this Agreement and the Ancillary
      Documents. The Buyer has taken all action necessary to authorize the execution
      and delivery of this Agreement and the Ancillary Documents, the performance
      of
      its obligations hereunder and thereunder, and the consummation of the
      transactions contemplated hereby and thereby.

    

    5.3    Enforceability.
      This Agreement and the Ancillary Documents have been duly authorized by all
      necessary corporate action, executed and delivered by the Buyer and constitute
      the legal, valid and binding obligation of the Buyer, enforceable against it
      in
      accordance with its terms, except as the same may be limited by applicable
      bankruptcy, insolvency, reorganization, moratorium or similar laws affecting
      the
      enforcement of creditors’ rights generally and general equitable principles
      regardless of whether such enforceability is considered in a proceeding at
      law
      or in equity.

    

    5.4    No
      Default or Consents.  Neither
      the execution or delivery of this Agreement and the Ancillary Documents by
      Buyer, nor the carrying out of the transactions contemplated hereby will:
      (a) violate
      the Articles of Incorporation or Bylaws of the Buyer; (b) violate,
      conflict with, result in a breach of, constitute a default under (whether with
      or without notice or the lapse of time or both), or accelerate or permit the
      acceleration of the performance required by, or give any other party the right
      to terminate, any material contract or other instrument applicable to Buyer;
      (c) result
      in the creation of any material lien, charge or other encumbrance on any
      property of the Buyer; (d) require
      the Buyer to obtain or make any waiver, consent, action, approval or
      authorization of, or registration, declaration, notice of filing with, any
      private non-governmental third party or any governmental agency, except as
      otherwise required under applicable federal securities laws, or (e) violate
      or conflict with any law, statute, ordinance, rule, regulation, judgment, order,
      injunction, or decree to which the Buyer is a party, or by which the Buyer
      is
      bound.

    

    5.5    No
      Proceedings. No suit, action or other proceeding is pending or, to the
      Buyer’s knowledge, threatened by any third party seeking to restrain the Buyer
      or prohibit Buyer’s entry into this Agreement or the Ancillary Documents or
      prohibit the Closing, or seeking damages against the Buyer or Buyer’s properties
      as a result of the consummation of this Agreement.

    

    5.6    No
      Other Consideration.
      The only
      consideration being paid by the Buyer for the Stock is the Sequiam Shares and
      no
      other consideration in any form whatsoever (including, but not limited to,
      any
      real or personal property, securities or cash) has been or will be received
      by
      the Buyer in exchange for the Sequiam Shares.

    

    5.7    Investment.
      The Buyer is purchasing the Stock for its own account for investment, and not
      with a view to the resale or distribution thereof in violation of any applicable
      securities laws. The officers and directors of Buyer have such knowledge and
      experience in financial and business matters that they are able to evaluate
      the
      merits and risks of the Buyer aquiring the Stock and to make an informed
      investment decision relating thereto. 

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

    

    

    5.8    Brokers.
      No broker or finder is involved in connection with this transaction or is
      entitled to receive a fee, commission or other compensation from the Buyer
      with
      respect to the transactions contemplated in this Agreement.

    

    5.9    Authorization. The
      Buyer
      has duly authorized the issuance of the Sequiam Shares to the Shareholders
      by
      all necessary corporate action and, when paid for in accordance with the terms
      of this Agreement, the Sequiam Shares will be validly issued and outstanding,
      fully paid and nonassessable shares of common stock of Buyer.

    

    6.    THE
      SHAREHOLDERS’ OBLIGATIONS BEFORE THE CLOSING DATE.

    

    The
      Shareholders, jointly and severally, hereby covenant and agree that, from the
      date hereof until the Closing Date:

    

    6.1    Corporate
      Matters. Except as otherwise contemplated by this Agreement, neither the
      Company nor the Subsidiary will, without the prior written consent of the Buyer,
      permit the Company or the Subsidiary to:

    

    (a)    amend
      its
      Articles of Incorporation or By-Laws or other applicable governing
      document;

    

    (b)    issue
      any
      shares of the Company’s or Subsidiary’s capital stock;

    

    (c)    issue
      or
      create any warrants, obligations, subscriptions, options, convertible securities
      or other commitments under which any additional shares of the Company’s or
      Subsidiary’s capital stock might be directly or indirectly issued; 

    

    (d)    declare,
      pay, set aside or make any dividend(s) or other distribution(s) of cash or
      other
      property, or redeem any outstanding shares of the Company’s or Subsidiary’s
      capital stock;

    

    (e)    forgive
      any liability or indebtedness owed to the Company or Subsidiary by any
      Shareholder or any of his Affiliates; 

    

    (f)    agree
      to
      do, or take any action in furtherance of, any of the foregoing.

    

    7.    [RESERVED].

    

    8.    CONDITIONS
      PRECEDENT TO THE BUYER’S PERFORMANCE.

    

    The
      obligations of the Buyer to consummate the transactions contemplated by this
      Agreement are further subject to the satisfaction, at or before the Closing
      Date, of all the following conditions, any one or more of which may be waived
      in
      writing by the Buyer:

    

    8.1    Accuracy
      of Representations and Warranties;. All representations and warranties made
      by the Shareholders in this Agreement, in any Schedule(s) hereto, and/or in
      any
      written statement delivered to the Buyer under this Agreement shall be true
      and
      correct in all material respects on and as of the Closing Date as though such
      representations and warranties were made on and as of that date.

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

    

    

    8.2    Performance.
      Each Shareholder shall have performed, satisfied and complied with all
      covenants, agreements, and conditions required by this Agreement to be
      performed, satisfied or complied with by the Shareholder on or before the
      Closing Date.

    

    8.3    Certification.
      The Buyer shall have received a certificate, dated the Closing Date, signed
      by
      each Shareholder, certifying, in such detail as the Buyer and its counsel may
      reasonably request, that the conditions specified in Sections 8.1 and 8.2 have
      been fulfilled.

    

    8.4    Absence
      of Litigation. No action, suit or proceeding by or before any court or any
      governmental body or authority, against the Company or pertaining to the
      transactions contemplated by this Agreement or their consummation, shall have
      been instituted on or before the Closing Date, which action, suit or proceeding
      would, if determined adversely, have a material adverse effect on the Company,
      the Subsidiary, their business or any material portion of their
      assets.

    

    8.5    Consents.
      All necessary disclosures to and agreements and consents of (a) any
      parties
      to any material contracts and/or any licensing authorities which are material
      to
      the Company’s business, and (b) any governmental authorities or agencies to
      the extent required in connection with the transactions contemplated by this
      Agreement, shall have been obtained and true and complete copies thereof
      delivered to the Buyer.

    

    8.6    No
      Material Adverse Change. On the Closing Date, there shall not have occurred
      any event or condition materially and adversely affecting the financial
      condition, results of operations or business prospects of the Company, except
      for matters resulting from adverse changes in economic conditions affecting
      businesses generally.

    

    8.7    Proceedings
      and Instruments Satisfactory. All proceedings, corporate or other, to be
      taken in connection with the transactions contemplated by this Agreement, and
      all documents incidental thereto, shall be reasonably satisfactory in form
      and
      substance to the Buyer and its counsel. 

    

    9.    CONDITIONS
      PRECEDENT TO EACH SHAREHOLDERS PERFORMANCE.

    

    The
      obligations of each Shareholder to consummate the transactions contemplated
      by
      this Agreement are further subject to the satisfaction, at or before the Closing
      Date, of all of the following conditions, any one or more of which may be waived
      in writing by the Shareholders:

    

    9.1    Accuracy
      of Representations and Warranties. All representations and warranties made
      by the Buyer in this Agreement and/or in any written statement delivered by
      the
      Buyer under this Agreement shall be true and correct in all material respects
      on
      and as of the Closing Date as though such representations and warranties were
      made on and as of that date.

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

    

    

    9.2    Performance.
      The Buyer shall have performed, satisfied and complied with all covenants,
      agreements and conditions required by this Agreement to be performed, satisfied
      or complied with by the Buyer on or before the Closing Date.

    

    9.3    Certification.
      The Shareholder shall have received a certificate, dated the Closing Date,
      signed by the Buyer, certifying, in such detail as the Shareholder and his
      counsel may reasonably request, that the conditions specified in Sections 9.1
      and 9.2 have been fulfilled.

    

    9.4    Proceedings
      and Instruments Satisfactory. All proceedings to be taken in connection with
      the transactions contemplated by this Agreement, and all documents incidental
      thereto, shall be reasonably satisfactory in form and substance to the
      Shareholders and their counsel.

    

    10.   ADDITIONAL
      AGREEMENTS OF THE PARTIES.

    

    10.1    Assumption
      of Promissory Note by Buyer: The promissory note of the Company in favor of
      Lee Harrison Corbin, Attorney-in-Fact for the Trust under the Will of John
      Svenningsen (the “Trust”) in the principal amount of $200,000.00 and dated March
      23, 2005 [sic] (the “March Note”) shall be assumed by the Buyer and consolidated
      with the promissory note dated May 18, 2005 by Buyer in favor of the Trust
      in
      the principal amount of $3,450,000 (the “May Note”), and shall be subject to the
      same terms and conditions as the May Note. In connection therewith, the Buyer
      and the Company shall execute any and all documents necessary or reasonably
      desirable for the Company and its assets to become subject to, by joinder or
      otherwise, the security provisions securing the May Note, including but not
      limited to the Master Security Agreement dated May 18, 2005, the Stock Pledge
      Agreement dated May 18, 2005, a Subsidiary Guaranty, and all related documents
      executed in connection with the $3,450,000 loan (the “Loan’).

    

    10.2    Issuance
      of Warrant. The Buyer acknowledges that the common stock purchase warrant
      for 600,000 shares of common stock of the Buyer provided for under Section
      3 of
      the March Note was never issued and in lieu thereof, the Buyer agrees to issue
      such warrant to the Trust, which warrant shall have an exercise price of $0.14
      per share and shall expire on March 23, 2010.

    

    11.   INDEMNIFICATION.

    

    11.1    Survival.
      The representations, warranties, and indemnities of the parties set forth in
      this Agreement or in connection with the transactions contemplated hereby shall
      not survive the Closing. 

     

    11.2    Indemnity
      by the Shareholder.
      From
      and after the Closing, each Shareholder, individually and not jointly, hereby
      agrees to indemnify and hold harmless the Buyer and the Company and its
      Shareholders, directors, officers and employees (the “Buyer
      Indemnified Parties”),
      from
      and against any and all damages, liabilities, obligations, penalties, fines,
      interest, judgments, claims, deficiencies, losses, costs, expenses and
      assessments (including without limitation income and other taxes, interest,
      penalties and attorneys’ and accountants’ fees and disbursements) (“Damages”)
      suffered or incurred by the Buyer Indemnified Parties arising out of, resulting
      from or in any way related to a breach of, or the failure to perform or satisfy
      any of, the representations, warranties, covenants and agreements made by the
      Shareholder in this Agreement, or any certificate delivered by the Shareholder
      at the Closing pursuant hereto.

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    

    11.3    Post-Closing
      Indemnity by the Buyer. From and after the Closing, the Buyer hereby agrees
      to indemnify and hold harmless the Shareholder and his successors in interest,
      estate and beneficiaries (the “Shareholder
      Indemnified Parties”),
      from
      and against any and all Damages suffered or incurred by the Shareholder
      Indemnified Parties arising out of, resulting from or in any way related to:
      (a)
      a breach of, or the failure to perform or satisfy any of, the representations,
      warranties, covenants and agreements made by the Buyer in this Agreement, any
      Ancillary Document or certificate delivered by the Buyer at the Closing pursuant
      hereto; and (b) any litigation brought by (i) Constellation Biometrics Ltd.,
      a
      South African company (the “Seller”) and/or (ii) the shareholders of the
      shareholders of Seller or their respective heirs and legatees, in connection
      with the acquisition of the assets of the Seller by the Company. 

    

    11.4    Claims
      for Indemnity. For purposes of this Article 11, a party making a claim for
      indemnity under this Agreement is hereinafter referred to as an “Indemnified
      Party” and the party against whom such claim is asserted is hereinafter
      referred to as the “Indemnifying Party.” All claims by any Indemnified
      Party under this Agreement shall be asserted and resolved in accordance with
      the
      following provisions. If any claim or demand for which an Indemnifying Party
      would be liable to an Indemnified Party is asserted against or sought to be
      collected from such Indemnified Party by such third party, said Indemnified
      Party shall with reasonable promptness notify in writing the Indemnifying Party
      of such claim or demand stating with reasonable specificity the circumstances
      of
      the Indemnified Party’s claim for indemnification; provided,
however, that any failure to give such notice will not waive any rights
      of the Indemnified Party. After receipt by the Indemnifying Party of such
      notice, then upon reasonable notice from the Indemnifying Party to the
      Indemnified Party, or upon the request of the Indemnified Party, the
      Indemnifying Party shall defend, manage and conduct any proceedings,
      negotiations or communications involving any claimant whose claim is the subject
      of the Indemnified Party’s notice to the Indemnifying Party as set forth above,
      and shall take all actions necessary, including but not limited to the posting
      of such bond or other security as may be required by any governmental agency,
      so
      as to enable the claim to be defended against or resolved without expense or
      other action by the Indemnified Party. Upon request of the Indemnifying Party,
      the Indemnified Party shall, to the extent it may legally do so and to the
      extent that it is compensated in advance by the Indemnifying Party for any
      costs
      and expenses thereby incurred, (i) take such action as the Indemnifying Party
      may reasonably request in connection with such action, (ii) allow the
      Indemnifying Party to dispute such action in the name of the Indemnified Party
      and to conduct a defense to such action on behalf of the Indemnified Party,
      and
      (iii) render to the Indemnifying Party all such assistance as the Indemnifying
      Party may reasonably request in connection with such dispute and
      defense.

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

    

    

    11.5    Limitations
      on Certain Indemnity. The
      indemnification obligations of the parties hereto pursuant to this Agreement
      shall be limited to actual damages and shall not include incidental,
      consequential, indirect, punitive, special, or exemplary damages, except that
      any incidental, consequential, indirect, punitive, specific or exemplary damages
      recovered by any third party against any indemnified party under this Agreement
      shall be included in Damages recoverable under the indemnification obligations
      of the parties hereto pursuant to this Agreement. In
      any
      event, the aggregate liability of the Buyer under the indemnification
      obligations of the Buyer pursuant to this Agreement shall not exceed
      $175,000.00. In addition, the aggregate liability of any Shareholder under
      the
      indemnification obligations of the Shareholders hereunder pursuant to this
      Agreement shall not exceed the purchase price received by such Shareholder
      for
      the Shares sold hereunder, and the Buyer Indemnified Parties agree to look
      solely to the Shares issued to the Shareholder hereunder for indemnification,
      and the Shareholders shall not otherwise be liable to any Buyer Indemnified
      Party for any amount. 

    

    12.    MISCELLANEOUS.

    

    12.1    Effect
      of Headings. The Article and Section headings used in this Agreement and the
      titles of the Schedules hereto are included for purposes of convenience only,
      and shall not affect the construction or interpretation of any of the provisions
      hereof or of the information set forth in such Schedules. Whenever required
      by
      the context, and as used in this Agreement, the singular number shall include
      the plural and pronouns and any variations thereof shall be deemed to refer
      to
      the masculine, feminine, neuter, singular or plural.

    

    12.2    Entire
      Agreement; Waivers. This Agreement and the other agreements and instruments
      referred to herein constitute the entire agreement between the parties
      pertaining to the subject matter hereof, and supersede all prior agreements
      or
      understandings as to such subject matter. No party hereto has made any
      representation or warranty or given any covenant to the other except as set
      forth in this Agreement, the Schedules hereto, and the other agreements and
      instruments referred to herein. No waiver of any of the provisions of this
      Agreement shall be deemed, or shall constitute, a waiver of any other
      provisions, whether or not similar, nor shall any waiver constitute a continuing
      waiver. No waiver shall be binding unless executed in writing by the party
      making the waiver.

    

    12.3    Parties
      in Interest. Nothing in this Agreement, whether expressed or implied, is
      intended to confer any rights or remedies under or by reason of this Agreement
      on any persons other than the parties to it and their respective heirs,
      executors, administrators, personal representatives, successors and permitted
      assigns, nor is anything in this Agreement intended to relieve or discharge
      the
      obligations or liability of any third persons to any party to this Agreement,
      nor shall any provision give any third persons any right of subrogation or
      action over or against any party to this Agreement.

    

    12.4    Notices.
      All notices, requests, demands and other communications under this Agreement
      shall be in writing and shall be deemed to have been duly given on the date
      of
      service if served personally on the party to whom notice is to be given, on
      the
      day after the delivery thereof to a recognized overnight courier service for
      next-day delivery with all charges prepaid or billed to the account of the
      sender, or on the third day after mailing if mailed to the party to whom notice
      is to be given, by first class mail, registered or certified, postage prepaid,
      and properly addressed to the Shareholder at the address contained in the
      Company’s shareholder records, and if to the Company, c/o Mark Mroczkowski,
      Chief Financial Office, Sequiam Corporation, 300 Support Lane, Orlando, Florida
      32809, or to such other address as either party shall have specified by notice
      in writing given to the other party.

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

    

    12.5    Amendments
      and Modifications. No amendment or modification of this Agreement or any
      Schedule hereto shall be valid unless made in writing and signed by the party
      to
      be charged therewith. 

    

    12.6    Non-Assignability;
      Binding Effect. Neither this Agreement, nor any of the rights or obligations
      of the parties hereunder, shall be assignable by either party hereto without
      the
      prior written consent of the other party hereto. Otherwise, this Agreement
      shall
      be binding upon and shall inure to the benefit of the parties hereto and their
      respective heirs, executors, administrators, personal representatives,
      successors and permitted assigns.

    

    12.7    Governing
      Law; Jurisdiction; Venue; Waiver of Jury Trial. This Agreement and the
      documents delivered pursuant hereto shall be governed by and construed in
      accordance with the laws of the State of Florida without regard to any conflicts
      of law rules thereof. Each party hereto irrevocably submits to the exclusive
      jurisdiction of the Circuit Court of the State of Florida, Orange County, in
      any
      action or proceeding arising out of or relating to this Agreement or any of
      the
      Ancillary Documents, and each party hereby irrevocably agrees that all claims
      in
      respect of any such action or proceeding must be brought and/or defended in
      such
      court; provided, however, that matters which are under the exclusive
      jurisdiction of the Federal courts shall be brought in the Federal District
      Court for the Middle District of Florida. Each party hereto consents to service
      of process by any means authorized by the applicable law of the forum in any
      action brought under or arising out of this Agreement or any of the Ancillary
      Documents, and each party irrevocably waives, to the fullest extent each may
      effectively do so, the defense of an inconvenient forum to the maintenance
      of
      such action or proceeding in any such court. EACH PARTY HERETO HEREBY
      IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT IT MAY LEGALLY
      AND
      EFFECTIVELY DO SO, TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING ARISING
      HEREUNDER.

     

    12.8    Remedies.
      Except
      as set forth in Article 11, the rights and remedies provided by this Agreement
      are cumulative, and the use of any one right or remedy by any party hereto
      shall
      not preclude or constitute a waiver of its right to use any or all other
      remedies. Such rights and remedies are given in addition to any other rights
      and
      remedies a party may have by law, statute or otherwise.

     

    12.9    Exhibits.
      The
      exhibits referred to herein are attached hereto and incorporated herein by
      this
      reference. 

     

    12.10  
        Survival.
      Any
      provision of this Agreement which contemplates performance or the existence
      of
      obligations after the Closing Date, and any and all representations and
      warranties set forth in this Agreement, shall not be deemed to be merged into
      or
      waived by the execution and delivery of the instruments executed at the Closing,
      but shall expressly survive Closing and shall be binding upon the party or
      parties obligated thereby in accordance with the terms of this Agreement,
      subject to any limitations expressly set forth in this Agreement.

     

    12.11 
        Attorneys’
      Fees.
      In the
      event any suit or other legal proceeding is brought for the enforcement of
      any
      of the provisions of this Agreement, the parties hereto agree that the
      prevailing party or parties shall be entitled to recover from the other party
      or
      parties upon final judgment on the merits reasonable attorneys’ fees (and sales
      taxes thereon, if any), including attorneys’ fees for any appeal, and costs
      incurred in bringing such suit or proceeding.

    
      
        
        

      

      
        11

        
          

        

      

      
        
        

      

    

    

    12.12 
        Severability.
      If any provision of this Agreement is held by a court of competent jurisdiction
      to be contrary to law, then the remaining provisions of this Agreement, as
      applicable, if capable of substantial performance, shall remain in full force
      and effect.

    

    12.13 
        Further
      Assurances. From time to time from and after the Closing Date, the parties
      will execute and deliver to each other any and all further agreements,
      instruments, certificates and other documents as may reasonably be requested
      by
      the other party in order more fully to consummate the transactions contemplated
      hereby.

    

    12.14 
        Counterparts.
      This Agreement may be executed simultaneously in any number of counterparts,
      each of which shall be deemed an original, but all of which together shall
      constitute one and the same instrument.

    

    IN
      WITNESS WHEREOF, the
      parties have executed this Agreement on and as of the date first set forth
      above.

    

    
      	
              COMPANY:

            	
              BUYER:

            
	 	 
	
              CONSTELLATION
                BIOMETRICS CORPORATION

            	
              SEQUIAM
                CORPORATION

            
	 	 
	
              By: 
                /s/
                Nicholas VandenBrekel

            	
              By: 
                Mark
                L. Mroczkowski

            
	
              Name: 
                Nicholas VandenBrekel

            	
              Name: 
                Mark L. Mroczkowski

            
	
              Title: 
                President

            	
              Title: 
                Senior Vice President and Chief Financial
                Officer

            

    

     

    
      
        
        

      

      
        12

        
          

        

      

      
        
        

      

    

    

    
      	 	
              SELLERS:

            
	 	 
	 	
              /s/
                Walter H. Sullivan III

            
	 	
              Walter
                H. Sullivan, III

            
	 	 
	 	
              /s/
                Lee Harrision Corbin

            
	 	
              Lee
                Harrison Corbin, Attorney-in-Fact for the Trust under the Will of
                John
                Svenningsen

            
	 	 
	 	
              /s/
                Lee Harrison Corbin

            
	 	
              Lee
                Harrison Corbin

            
	 	 
	 	
              /s/
                Nick VandenBrekel

            
	 	
              Nick
                VandenBrekel

            
	 	 
	 	
              /s/
                Mark Mroczkowski

            
	 	
              Mark
                Mroczkowski

            

    

     

    
      
        
        

      

      
        13

        
          

        

      

      
        
        

      

    

    EXHIBIT
      A

     

    Constellation
      Biometrics Corporation

    

    Capitalization
      of Constellation

    Source
      of
      Funds and Shares

    

    
      	
              Shareholders

            	 	
              Percent
                Ownership

            	 	
              Shares

            	 	
              Capital
                Stock(1)

            	 	
              Loans(2)

            	 	
              Total
                Funds

            	 	
              Sequiam
                Common Shares(3)

            	 	
              Basis

              In

              Stock

            	 	
              Total
                Basis

            	 	
              Sequiam
                Share Exchange

            	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	
              Walter
                H. Sullivan III

            	 	 	
              32

            	
              %

            	 	
              320

            	 	
              $

            	
              4,800

            	 	
              $

            	
              30,200

            	 	
              $

            	
              35,000

            	 	 	
              80,000

            	 	 	
              14,400

            	 	 	
              49,400

            	 	 	
              461,682
                

            	 
	
              Svenningsen
                Trust

            	 	 	
              25

            	
              %

            	 	
              250

            	 	 	
              3,750

            	 	 	
              56,250

            	 	 	
              60,000

            	 	 	
              62,500

            	 	 	
              11,250

            	 	 	
              71,250

            	 	 	
              665,888
                

            	 
	
              Lee
                Harrison Corbin

            	 	 	
              7

            	
              %

            	 	
              70

            	 	 	
              1,050

            	 	 	
              8,950

            	 	 	
              10,000

            	 	 	
              17,500

            	 	 	
              3,150

            	 	 	
              13,150

            	 	 	
              122,897
                

            	 
	
              Nick
                VandenBrekel

            	 	 	
              18

            	
              %

            	 	
              180

            	 	 	
              2,700

            	 	 	
              9,800

            	 	 	
              12,500

            	 	 	
              45,000

            	 	 	
              8,100

            	 	 	
              20,600

            	 	 	
              192,523
                

            	 
	
              Mark
                Mroczkowski

            	 	 	
              18

            	
              %

            	 	
              180

            	 	 	
              2,700

            	 	 	
              9,800

            	 	 	
              12,500

            	 	 	
              45,000

            	 	 	
              8,100

            	 	 	
              20,600

            	 	 	
              192,523
                

            	 
	
              Total

            	 	 	
              100

            	
              %

            	 	
              1,000

            	 	
              $

            	
              15,000

            	 	
              $

            	
              115,000

            	 	
              $

            	
              130,000

            	 	 	
              250,000

            	 	 	
              45,000

            	 	 	
              175,000

            	 	 	
              1,635,514
                

            	 

    

    

    ___________________

    (1) Cash
      paid
      for stock.

    (2) Loans
      made to Company.

    (3) Shares
      of
      common stock of Sequiam Corporation contributed to the Company.

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    

    EXHIBIT
      B

     

    

    
      	
              Shareholders

            	 	
              Percent
                Ownership

            	 	
              Basis
                in CBC
                Stock

            	 	
              Sequiam
                Shares @
                $0.107* 

            	 
	 	 	 	 	 	 	 	 
	
              Walter
                H. Sullivan III

            	 	 	
              28

            	
              %

            	 	
              49,400
                

            	 	 	
              461,682
                

            	 
	
              Svenningsen
                Trust

            	 	 	
              41

            	
              %

            	 	
              71,250
                

            	 	 	
              665,888
                

            	 
	
              Lee
                Harrison Corbin

            	 	 	
              8

            	
              %

            	 	
              13,150
                

            	 	 	
              122,897
                

            	 
	
              Nick
                VandenBrekel

            	 	 	
              12

            	
              %

            	 	
              20,600
                

            	 	 	
              192,523
                

            	 
	
              Mark
                Mroczkowski

            	 	 	
              12

            	
              %

            	 	
              20,600
                

            	 	 	
              192,523
                

            	 
	
              Total

            	 	 	
              100

            	
              %

            	 	
              175,000
                

            	 	 	
              1,635,514
                

            	 

    

    

    *
      Market
      value $0.107 at closing.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00086-of-00352.parquet"}]]